Document Detail

Cost effectiveness of intensive treatment of hypertension. Based on presentations by Donald S. Shepard, PhD; and Dominic Hodgkin, PhD.
MedLine Citation:
PMID:  10339108     Owner:  NLM     Status:  MEDLINE    
The Hypertension Optimal Treatment (HOT) study showed that substantial reductions in blood pressure and a corresponding lowering of the risk of myocardial infarction could be achieved by intensive antihypertensive therapy. A cost-effectiveness analysis was performed to determine the possible economic consequences of three different targets of diastolic blood pressure lowering--< or = 90 mm Hg, < or = 85 mm Hg, and < or = 80 mm Hg, and of the coadministration of aspirin. The cost of each drug was first estimated at high and low dosage. Next, by drawing on data from the HOT trial, the mixture and dosage of drugs for each level of blood pressure control were estimated. This allowed computation of the annual cost of drugs for each blood pressure target. Because the rate of myocardial infarction (MI) was the only endpoint that differed significantly among the three target blood pressure groups, the MI risk data were converted into years of life gained on the basis of fatalities from MI averted. The cost-effectiveness ratios, expressed as cost per year of life gained, were most favorable for the < or = 90-mm Hg treatment target group ($4262) and for added aspirin treatment ($12,710). For moderately aggressive treatment (blood pressure < or = 85 mm Hg), the cost-effectiveness ratio escalated incrementally to $86,360 and with intensive treatment to $658,370 per year of life gained. Thus treatment to a target of 90 mm Hg and coadministering aspirin were considered highly cost effective, whereas treatments to lower the blood pressure further to 85 mm Hg were marginally cost effective; intensive blood pressure lowering down to 80 mm Hg was not cost effective.
Related Documents :
356078 - Treatment of hypertension with biofeedback and relaxation techniques.
19344738 - Longitudinal evaluation of the effect of smoking initiation on body weight, blood press...
23248828 - Utility of cocaine drug screens to predict safe delivery of general anesthesia for elec...
9083288 - Low diastolic blood pressure, hypoalbuminemia, and risk of death in a cohort of chronic...
8342198 - Use of neuroanesthesia adjuncts (hyperventilation and mannitol administration) improves...
8102598 - Cardiac noradrenergic nerve terminal abnormalities in dogs with experimental congestive...
Publication Detail:
Type:  Congresses    
Journal Detail:
Title:  The American journal of managed care     Volume:  4     ISSN:  1088-0224     ISO Abbreviation:  Am J Manag Care     Publication Date:  1998 Dec 
Date Detail:
Created Date:  1999-02-25     Completed Date:  1999-02-25     Revised Date:  2005-07-26    
Medline Journal Info:
Nlm Unique ID:  9613960     Medline TA:  Am J Manag Care     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  S765-9; discussion S770     Citation Subset:  H    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antihypertensive Agents / economics,  therapeutic use
Aspirin / therapeutic use
Cost of Illness*
Cost-Benefit Analysis / statistics & numerical data
Hypertension / drug therapy*,  economics*
Myocardial Infarction / economics,  prevention & control
Quality-Adjusted Life Years*
United States
Reg. No./Substance:
0/Antihypertensive Agents; 50-78-2/Aspirin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Hypertension and managed care. Based on a presentation by Robert P. Jacobs, MD, MBA.
Next Document:  Disease management programs help cut costs, improve care.